Hints and tips:
...At their worst, Allergan shares were down 8.5 per cent in response to the news. In a short statement just over three hours later, the company U-turned....
...Michael E Greenberg has joined the board of drug company Allergan. He will replace Fred G Weiss, who plans to step down in October....
...Teva in December paid more than $500m to settle U.S. charges that it violated bribery laws at its operations in Ukraine, Mexico and Russia....
...Pfizer said in a statement: The decision was driven by the actions announced by the U.S....
...Shortly after Mrs Clinton’s intervention, the company performed a partial U-turn, introducing a discount card and promising to launch a cut-price generic version....
...Quartz reports breathlessly that the “mid-life crisis is real”, citing a University of Warwick study showing that age plotted against happiness produces a U-shaped curve....
...Mike Pearson, Valeant’s chief executive, had faced the prospect of missing out on a second big deal, after his year-long pursuit of Botox maker Allergan was thwarted by a rival $70bn bid from Actavis....
...The position is expected to make the prominent U.S. hedge fund, led by John Paulson, one of the top 10 to 15 holders of Allergan, according to Thomson Reuters shareholder data as of March 31.”...
...Allergan, which is fending off a takeover attempt from Valeant Pharmaceuticals, has also been rumored as a bidder for Shire.”...
...(WSJ) “Ford Motor Chief Executive Alan Mulally will leave the company earlier than expected after a more than seven-year run in which he oversaw a significant expansion of the U.S. auto maker, people familiar...
...A bid by Allergan for Shire, which has a market value of $32 billion, would underscore how keen the U.S. dermatology drugmaker is to stay independent.”...
...There was also a buzz round Allergan....
International Edition